Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbbVie (DE:4AB)
XETRA:4AB
AbbVie (4AB) Stock Price & Analysis
10 Followers
4AB Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€115.42 - €167.35
Previous Close€155.22
Volume3.00
Average Volume (3M)712.00
Market Cap
€276.18B
Enterprise Value€319.88B
Total Cash (Recent Filing)$12.82B
Total Debt (Recent Filing)$59.38B
Price to Earnings (P/E)61.7
Beta0.02
Next Earnings
Apr 26, 2024EPS Estimate
€2.12Next Dividend Ex-DateN/A
Dividend Yield3.6%
Share Statistics
EPS (TTM)2.51
Shares Outstanding1,766,473,359
10 Day Avg. Volume773
30 Day Avg. Volume712
Standard Deviation0.07
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-3.79
Price to Sales (P/S)19.17
Price to Cash Flow (P/CF)15.50
P/FCF Ratio15.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.89
Enterprise Value/Gross Profit9.44
Enterprise Value/Ebitda19.97
Forecast
1Y Price Target
€174.63Price Target Upside13.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
AbbVie News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceHigh return on equity at 34.90% signals strong financial performance.
Market PotentialRinvoq and Skyrizi are showing robust prescription growth, which could lead to stronger ex-US sales.
Strategic AcquisitionsThe acquisition of ImmunoGen by AbbVie was completed ahead of schedule, lifting remaining overhang related to potential FTC risk.
Bears Say
CompetitionHeme-onc sales could slightly miss due to competition, with Imbruvica and Venclexta demand softer year over year.
Product DemandMavyret could miss by $45M as the current consensus does not adequately reflect the widening demand erosion.
Sales PerformanceAesthetics may be a source of weakness, with Botox sales possibly surprising to the downside by $30M versus consensus estimates.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.27% Insiders
21.54% Mutual Funds
21.16% Other Institutional Investors
57.03% Public Companies and
Individual Investors
4AB FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was €115.42 and its highest was €167.35 in the past 12 months.
What is AbbVie’s market cap?
Currently, no data Available
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Apr 26, 2024 which is in 3 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Feb 02, 2024. The company reported €2.616 earnings per share for the quarter, missing the consensus estimate of €2.618 by -€0.003.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie does not currently pay dividends.
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is €2.12.
How many shares outstanding does AbbVie have?
AbbVie has 1,770,647,000 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of €2.616 in its last earnings report, missing expectations of €2.618. Following the earnings report the stock price went up 2.68%.
Which hedge fund is a major shareholder of AbbVie?
Among the largest hedge funds holding AbbVie’s share is Diamond Hill Capital Management Inc. It holds AbbVie’s shares valued at 208M.
---
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€174.63 (13.27% Upside)
€174.63 (13.27% Upside)
Blogger Sentiment
Bullish
DE:4AB Sentiment 94%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $81.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.41%
12-Months-Change
Fundamentals
Return on Equity
34.90%
Trailing 12-Months
Asset Growth
-2.95%
Trailing 12-Months
Company Description
AbbVie
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
---
4AB Company Deck
---
4AB Earnings Call
Q4 2024
0:00 / 0:00
---
4AB Net revenue Breakdown
48.12% Immunology
14.21% Neuroscience
12.59% Other Key Products
10.89% Oncology
14.19% Other
---
4AB Stock 12 Months Forecast
Average Price Target
€174.63
▲(13.27% Upside)
Technical Analysis
Best Analysts Covering 4AB
1 Year
1 Year Success Rate
20/23 ratings generated profit
1 Year Average Return
+16.88%
reiterated a buy rating 5 months ago
Copying Gary Nachman's trades and holding each position for 1 Year would result in 86.96% of your transactions generating a profit, with an average return of +16.88% per trade.
---